Table 3.
Summary of CEA levels in benign lung diseases reported in the literature.
| Author | N | Cutoff (ng/mL) | N of CEA > cutoff | Maximum value | Type of disease |
|---|---|---|---|---|---|
| Schneider et al.10 | 106 | 6.4 | 0 | 6.4 | Pneumonitis and COPD |
| Sharma et al.11 | 18 | 5 | 1 (5.56%) | 6.8 | Tuberculosis |
| Wang et al.12 | 87 | 9.8 | 2 (2.3%) | 10.8 | Tuberculosis; pulmonary infection; COPD |
| Kulpa et al.13 | 96 | 4 | 5 (5.2%) | 9.5 | Sarcoidosis; tuberculosis; fibrosis, asthma; hamartoma; noncancerous tumors; pneumonitis |
| Nisman et al.14 | 85 | 5 | 6 (7.05%) | 10a | Infectious lung diseases; diffuse noninfectious lung diseases; COPD |
| Song et al.15 | 124 | 5 | 7 (5.65%) | 8.93 | Tuberculosis; inflammatory pseudotumor; other benign tumors |
| Beržinec et al.16 | 10 | 4.61 | 1 (10%) | 6.37 | Benign respiratory tract diseases |
| Gruber et al.17 | 318 | 12 | 10 (3.14%) | 20a | Tuberculosis; pneumonitis; pleural effusion; sarcoidosis; fibrosis; COPD; Benign lung tumors; others |
| Fahim et al.18 | 41 | 5 | 21 (51%) | 26a | Idiopathic pulmonary fibrosis |
| Total | 885 | 53 (5.99%) |
COPD Chronic obstructive pulmonary disease.
aApproximate value.